Paul Dietze combines experience as a chemist and a lawyer to advise clients on all aspects of intellectual property in life sciences and chemical industries. His background as a chemistry professor and research chemist helped him develop an in-depth understanding of the technological issues in these areas so that he can provide a thorough, comprehensive approach to solving the legal challenges his clients face.
Paul works closely with clients in preparing opinions addressing patent non-infringement and/or invalidity, analyzing their portfolios, developing and implementing strategic patent programs, prosecuting patents, and providing litigation support.
He has provided clients hundreds of non-infringement and/or invalidity opinions in the chemical and pharmaceutical arts. He has considerable experience in the pharmaceutical industry, with a particular focus on preparing opinions clearing generic versions of pharmaceutical products. He has extensive experience with the Hatch-Waxman Act and has prepared opinions on patents covering dozens of drug products. His clients include some of the world’s largest generic pharmaceutical companies.
In addition, he has prosecuted and obtained patents for clients on new chemical entities, pharmaceutical delivery systems, cosmetics, flavors, foods and food additives, petroleum products, fragrances, polymers and polymer additives, glass coatings and catalysts. His experience in patent prosecution involves both domestic and foreign prosecution and includes drafting applications, responding to office actions, interviewing examiners, obtaining patent term extensions, handling reissue and reexamination proceedings, and preparing appeal briefs and arguing appeals at the Patent Trial and Appeal Board (PTAB). He has successfully argued several appeals before the PTAB.
Prior to becoming a patent attorney, Paul was a chemistry professor who taught a variety of graduate and undergraduate chemistry courses and supervised a funded research group. He also spent more than four years at the U.S. Food and Drug Administration (FDA) as a review chemist in the Division of Oncologic Drug Products. Additionally, he was a postdoctoral research fellow in the Brandeis University Graduate Department of Biochemistry from August 1984 to September 1987. He is the author of more than 15 publications in peer-reviewed scientific journals.